Page 39 of 440: studies 381 to 390 of 4,400, newest first. Back to the psilocybin overview
2026 Yosr Ziadi, Taehwan Park preprint
Conference poster presented at ISPOR 2026, Philadelphia, May 2026. Co-authors: Yosr Ziadi, Taehwan Park. St. John's University.
Cahiers francophones de soins palliatifs 2026 Michel Dorval, Sue-Ling Chang, Houman Farzin et al.
La psychothérapie assistée par psilocybine représente un ajout prometteur aux interventions de soins palliatifs, pouvant améliorer la qualité de vie en soulageant la détresse existentielle. Malgré sa sécurité et son efficacité, cette thérapie demeure limitée au Canada, soulignant la nécessité d’en améliorer l'accès pour atténuer la souffrance liée à des maladies potentiellement mortelles....
2026 Tom Bielen preprint
Psilocybin-assisted therapy has produced promising results in clinical trials for depression, but most existing reviews treat major depressive disorder (MDD) and treatment-resistant depression (TRD) as a single category. This conflation is a problem. MDD and TRD differ in diagnostic criteria, illness severity, prior treatment failure, and likely neurobiological profile. Pooling their results...
2026 Irina Dell'Orto preprint
Background: Psilocybin-assisted therapy (PAT) has demonstrated rapid and substantial antidepressant effects in phase 2 RCTs (Davis et al., 2021; Carhart-Harris et al., 2021), and phase 3 trials are now active (Usona uAspire, NCT06308653). However, three critical gaps remain unresolved in 2025: (1) the durability of effects beyond 12 months has not been established in a controlled design; (2)...
2026 Diego Monasterio López
Psychedelic experiences have shown promise in addressing mental health challenges (Doblin et al., 2019). Among these, ego dissolution is a central phenomenon associated with lasting therapeutic effects, involving a temporary disruption of the neurocognitive self-model that loosens entrenched patterns of rumination and self-reference (Kałużna et al., 2022; Letheby, 2021; Deane, 2020; Nour et...
2026 Canyon Akromis, Lorraine Li, Kwon Mok Ko et al. preprint
This project is a secondary analysis of data from Psilocybin in Depression Resistant to Standard Treatments (PsiDeR) study, a phase II, randomised, placebo-controlled clinical trial where participants with treatment resistant depression received either 25 mg of psilocybin or a placebo alongside psychotherapy. This research seeks to determine whether the therapeutic alliance, measured by the...
Open Mind 2026 Amin Nazmuddin Mohammadi, Christine Wekerle preprint
Alcohol use disorder (AUD) is a prevalent and chronic psychiatric condition characterized by impaired control over alcohol use, compulsive consumption, and high rates of relapse (Grant et al., 2015; Kurihara, 2023). Despite the availability of pharmacological and psychosocial interventions, treatment outcomes remain suboptimal, with substantial rates of non-response and relapse (Lohoff, 2022;...
SSRN Electronic Journal 2026 Amanda Elyse preprint
Psilocybin is the primary psychoactive compound in “magic mushrooms”; it has been used by humans for millennia, it is in promising clinical trials with humans and used in legalized psilocybin-assisted therapy, and researchers use and are further developing human-based methods with cutting-edge technologies. However, researchers are still allowed to conduct unreliable and distressing psilocybin...
Journal of the Brazilian Chemical Society 2026 Mateus Araújo Da Luz, Taynah Pereira Galdino, Lucas Matheus da S. Oliveira et al.
Psilocybin is a molecule with significant potential for the treatment of mental disorders such as depression, anxiety, post-traumatic stress disorder, and substance abuse. In this study, it was explored the extraction of psilocybin from Psilocybe cubensis mushrooms using a factorial design approach, along with the physicochemical and phytochemical characterization of the extracted material,...
Frontiers in Psychiatry 2026 Sivert Drange, Jacob Cohen, Sys Stybe Johansen et al. 1 citation
Obsessive-Compulsive Disorder (OCD) can present significant challenges to individuals mental health, characterized by intrusive thoughts and repetitive maladaptive behaviors. Recent research into alternative treatments has highlighted psychedelics, notably psilocybin, for their potential therapeutic benefits in various psychiatric disorders, including OCD. This case study evaluated the impact...